Drugs that contain Eslicarbazepine Acetate
1. Drug name - APTIOM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9206135 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 years from now) | |
| CN101277937A | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| CN101277937B | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| IN200801071P1 | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| IN263294B | SUNOVION PHARMS INC | A Process For Preparing (S) Or (R) -10,11-Dihydro-10-Hydroxy-5H-Dibenz[B,F] Azepine-5-Carboxamide |
Apr, 2026
(3 years from now) | |
| EP2319836B1 | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| EP2319836A1 | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| EP1915346A1 | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| EP1915346B1 | SUNOVION PHARMS INC | Asymmetric Catalytic Reduction Of Oxcarbazepine |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702536 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US10695354 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US10675287 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US9643929 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 years from now) | |
| US9763954 | SUNOVION PHARMS INC | Therapeutical uses of eslicarbazepine |
Sep, 2028
(5 years from now) | |
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(6 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(6 years from now) | |
| US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(7 years from now) | |
| US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(9 years from now) | |
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine; Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Prescription |
| 400MG | TABLET;ORAL | Prescription |
| 600MG | TABLET;ORAL | Prescription |
| 800MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.